Pharmicell to Expand Global Business Cooperation at "CPHI Milan 2026"

Pharmicell, a bio-materials company, is expanding its business cooperation with global clients.

Pharmicell announced on October 7 that it will participate in "CPHI Milan 2026," which is being held in Milan, Italy, until October 8. CPHI is one of the largest exhibitions in the world covering the entire pharmaceutical and bio value chain. This year, more than 2,900 exhibitors from over 170 countries and more than 62,000 visitors are expected to attend.

Pharmicell is operating a booth within the Korea Pavilion, presenting methoxypolyethylene glycol (mPEG) and related PEG derivatives as well as nucleosides as its core products—these are used in pharmaceuticals and bio materials. In particular, the company will showcase its nucleic acid materials lineup such as deoxynucleoside triphosphates (dNTPs) and nucleoside triphosphates (NTPs), which are utilized in the research, development, and production of oligonucleotide and nucleic acid-based pharmaceuticals, along with its newly developed nucleoside product line.

On site, Pharmicell will also hold business meetings with existing and potential new clients. The company will meet with UCB, Thermo Fisher Scientific, Clariant, Gannet Bio, Curapath, Innovassynth, and others, to review current product sales and supply status, as well as to discuss future demand prospects and mid- to long-term supply plans.

A Pharmicell representative stated, "Through this exhibition, we plan to identify diverse needs and requirements from global pharmaceutical and biotech clients and enhance our corporate and product awareness. Based on this, we will work to expand sales in the global market and establish a solid foundation for mid- to long-term business growth."

This content was produced with the assistance of AI translation services.